Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), GL3 inhibitors(Globotriaosylceramide inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Burkitt Lymphoma | Preclinical | Germany | 01 Jan 2026 |






